GSK Gsk Plc

   By Dominic Chopping 
 

Danish pharmaceutical company Genmab A/S (GEN.KO) said Wednesday that net sales of leukemia drug Arzerra (ofatumumab) during the second quarter of 2014 were GBP12.8 million.

This figure consists of net sales in the US of GBP6.9 million and in the rest of the world of GBP5.9 million.

Under the terms of the collaboration with GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of approximately DKK23 million.

The second quarter net sales did not include sales related to the supply of ofatumumab for clinical trials run by other parties.

-Write to Dominic Chopping at dominic.chopping@wsj.com; Twitter: @WSJNordics

Subscribe to WSJ: http://online.wsj.com?mod=djnwires